Does Adjuvant Systemic Therapy with Interferon- for Stage II–III Melanoma Prolong Survival?

Author： Eggermont A.M.M.  

Publisher： Adis International

ISSN： 1175-0561

Source： American Journal of Clinical Dermatology, Vol.4, Iss.8, 2003-01, pp. : 531-536

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prognostic role of liver X receptor‐alpha in resected stage II and III non‐small‐cell lung cancer

By  

THE CLINICAL RESPIRATORY JOURNAL, Vol. 12, Iss. 1, 2018-01 ,pp. : 241-246

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interferon Therapy for Malignant Solid Tumors

By  

Current Drug Therapy, Vol. 5, Iss. 2, 2010-05 ,pp. : 132-138

Bentham Science Publishers

Access to resources Recommend Favorite

Atopic Dermatitis: The Role of Recombinant Interferon- Therapy

By Chang T.T.   Stevens S.R.  

American Journal of Clinical Dermatology, Vol. 3, Iss. 3, 2002-03 ,pp. : 175-183

Adis International

Access to resources Recommend Favorite

Improving Survival in Patients with High-Risk and Metastatic Melanoma: Immunotherapy Leads the Way

By Agarwala S.S.  

American Journal of Clinical Dermatology, Vol. 4, Iss. 5, 2003-01 ,pp. : 333-346

Adis International

Access to resources Recommend Favorite

Imatinib: As Adjuvant Therapy for Gastrointestinal Stromal Tumor†: Profile Report

By Sanford Mark   Scott Lesley J.  

BioDrugs, Vol. 25, Iss. 3, 2011-06 ,pp. : 191-192

Adis International

Access to resources Recommend Favorite